Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864632 | 1.00 | FOLH1 (0.45) | FOLH1CHIT1DPP4S1PR1DPP7 | |
| SCHEMBL1996255 | 1.00 | FOLH1 (0.45) | FOLH1CHIT1DPP4S1PR1DPP7 | |
| SCHEMBL1079200 | 1.00 | FOLH1 (0.45) | FOLH1CHIT1DPP4S1PR1DPP7 | |
| SCHEMBL15904929 | 1.00 | FOLH1 (0.45) | FOLH1CHIT1DPP4S1PR1DPP7 | |
| Hydrochloric Acid SCHEMBL31226505 | 0.99 | FOLH1 (0.44) | FOLH1CHIT1DPP4S1PR1DPP7 | |
| SCHEMBL436094 | 0.94 | LMNA (0.45) | FOLH1CHIT1DPP4S1PR1CA1 | |
| SCHEMBL23627788 | 0.93 | HSD17B10 (0.44) | FOLH1CHIT1DPP4 | |
| SCHEMBL12974377 | 0.93 | FOLH1 (0.41) | FOLH1CHIT1DPP4SIGMAR1 | |
| SCHEMBL4098689 | 0.93 | HSD17B10 (0.44) | FOLH1CHIT1DPP4 | |
| SCHEMBL12261650 | 0.93 | FOLH1 (0.41) | FOLH1CHIT1DPP4S1PR1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20220401593-A1 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20220008568-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-01-13 | — | — | US | disclosed |
| US-20220008566-A1 | Pharmaceutical Composition Comprising a Radiolabeled GRPR Antagonist and a Surfactant | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-01-13 | — | — | US | disclosed |
| US-20210346528-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2021-11-11 | — | — | US | disclosed |
| US-20210346529-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2021-11-11 | — | — | US | disclosed |
| US-11083805-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2021-08-10 | — | — | US | disclosed |
| EP-3536347-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | Advanced Accelerator Applications USA, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2900279-B1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | ADVANCED ACCELERATOR APPLICATIONS USA INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20180133349-A1 | Radiolabeled GRPR-Antagonists For Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2018-05-17 | — | — | US | disclosed |
| US-20180133349-A1 | Radiolabeled GRPR-Antagonists For Diagnostic Imaging and Treatment of GRPR-Positive Cancer | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2018-05-17 | — | — | US | disclosed |
| US-9839703-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | ADVANCED ACCELERATOR APPLICATIONS USA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839703-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | ADVANCED ACCELERATOR APPLICATIONS USA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150265732-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2015-09-24 | — | — | US | disclosed |
| US-20150265732-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150265732-A1 | GRPR-ANTAGONISTS FOR DETECTION, DIAGNOSIS AND TREATMENT OF GRPR-POSITIVE CANCER | GRPR, GIPR, CCKBR | FOLH1 156/4885CHIT1 2977/4885DPP4 1226/4885 |
| US-20180133349-A1 | Radiolabeled GRPR-Antagonists For Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | FOLH1 145/4885CHIT1 2849/4885DPP4 1353/4885 |
| US-20210346528-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | FOLH1 145/4885CHIT1 2849/4885DPP4 1353/4885 |
| US-20210346529-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | FOLH1 145/4885CHIT1 2849/4885DPP4 1353/4885 |
| US-20220401593-A1 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | RAB5IF, TMEM14C, PAICS | FOLH1 282/4885CHIT1 2681/4885DPP4 3435/4885 |
| US-20220008566-A1 | Pharmaceutical Composition Comprising a Radiolabeled GRPR Antagonist and a Surfactant | GRPR, GIPR, SCTR | FOLH1 214/4885CHIT1 2601/4885DPP4 679/4885 |
| US-20220008568-A1 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | GRPR, GIPR, CCKBR | FOLH1 145/4885CHIT1 2849/4885DPP4 1353/4885 |
| US-11083805-B2 | Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer | GRPR, GIPR, CCKBR | FOLH1 145/4885CHIT1 2849/4885DPP4 1353/4885 |
| US-20230321287-A1 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | GRPR, GIPR, SCTR | FOLH1 138/4885CHIT1 2250/4885DPP4 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.